Header Logo

Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.

Carrino JA, McAlindon TE, Schnitzer TJ, Guermazi A, Hochberg MC, Conaghan PG, Brown MT, Burr A, Fountaine RJ, Pixton GC, Viktrup L, Verburg KM, West CR. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage. 2023 Dec; 31(12):1612-1626.

View in: PubMed